驱动基因阳性IV期非小细胞肺癌的治疗:ASCO动态指南2024.3版
ASCO动态指南针对驱动基因阳性的IV期非小细胞肺癌,由常设专家组持续系统复习文献并定期更新推荐。本版本未在摘要中列出具体推荐条款。
要点
- 本指南为ASCO动态指南,针对驱动基因阳性的IV期非小细胞肺癌。
- 由常设专家组持续系统复习文献并定期更新。
- 本版本摘要未报告具体推荐条款及数值。
核心结论
- 本动态指南针对驱动基因阳性的IV期非小细胞肺癌,推荐随证据更新而定期修订,摘要未给出具体推荐内容。
研究设计与样本
- 由常设专家组按ASCO指南方法学手册持续系统复习文献,定期更新推荐。
临床怎么用
- 原文指出动态指南及更新不能替代治疗临床医生的独立专业判断,也未考虑患者个体差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.
引用
- Owen DH, Ismaila N, Ahluwalia A, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3. J Clin Oncol. 2025. PMID: 40014839. doi:10.1200/JCO-24-02785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。